Cadrenal Therapeutics (CVKD) CEO Quang Pham Sells $1.6K of Stock
Quang Pham sold 513 shares of Cadrenal Therapeutics, raising $1,621.
Reviewed by automated data checks against the source filing. How we make and check alerts
Quang Pham, Chairman, CEO and Interim CFO at Cadrenal Therapeutics, Inc. ($CVKD), sold 513 shares at an average price of $3.16, worth about $1,621.08, on June 17, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $CVKD is down 3.9% after 1 week, down 30.3% after 1 month and down 64.8% to date (from the $3.10 close on Jun 17, 2026).
CVKD
Cadrenal Therapeutics, Inc.
Key Points
- Quang Pham, CEO of Cadrenal Therapeutics, sold 513 shares on June 17, 2026, for $1,621.08.
- Cadrenal Therapeutics, Inc., a Nasdaq-listed biotech firm, develops therapies for immune and thrombotic conditions.
- The company has a market cap of $9.5 million and a 52-week high of $14.64, with no dividend payout.
Get $CVKD trade alerts by text
We text you when insiders, Congress or big funds trade $CVKD. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cadrenal Therapeutics, Inc. alert may contain errors. Disclosures
Quang Pham, the Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc. (NasdaqCM: CVKD), sold 513 shares of the company on June 17, 2026. The shares were sold at an average price of $3.16, amounting to a total transaction value of $1,621.08. The sale was part of a planned transaction under Rule 10b5-1.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc. is a biotechnology company based in Ponte Vedra, Florida. It focuses on developing innovative therapies for serious immune and thrombotic conditions. The company is working on Tecarfarin, an oral medication in Phase 3 trials aimed at preventing heart attacks and strokes in patients needing long-term anticoagulation. Cadrenal is also developing CAD-1005 and Frunexian, targeting heparin-induced thrombocytopenia and acute hospital settings, respectively. Founded in 2022, Cadrenal collaborates with Abbott Global Enterprises Limited to enhance Tecarfarin's efficacy and safety.
Cadrenal Therapeutics, Inc. Stock Up 227.1%
Shares of Cadrenal Therapeutics are trading near $3.50. The company has a market capitalization of approximately $9.5 million. Although the company is not currently profitable, it has a forward P/E ratio of -0.79. The stock's beta is 1.613, indicating higher volatility than the market. Over the past year, the stock has ranged from a low of $3.02 to a high of $14.64. Its 50-day moving average is $5.02, and the 200-day moving average is $8.50. Cadrenal maintains a current ratio of 2.68 and a quick ratio of 2.17, reflecting its liquidity position.
Bottom Line
Quang Pham's recent sale of Cadrenal Therapeutics shares is part of a planned transaction, highlighting the structured approach executives often take in managing their holdings. Investors keep an eye on insider sales for insights into management's views on the company's prospects. As a late-stage biopharmaceutical firm, Cadrenal Therapeutics' ongoing clinical trials and collaborations remain crucial for its future growth. The company's financial metrics, such as its market cap and stock volatility, offer additional context for stakeholders.
Related Filing Alerts
Source: Quang Pham's Form 4 filing on $CVKD (Jun 17, 2026). Find the original filing: CVKD Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts